aibioInterpace Biosciences expects third quarter revenue of $10.1 million to $10.4 million
Tickers IDXG
The preliminary, unaudited range is approximately 11% to 14% above the second quarter of 2026 and approximately 15% to 18% above the third quarter of 2025.
Key facts
- Company
- INTERPACE BIOSCIENCES, INC. (OTC: IDXG)
- News type
- Company Updates
- Primary source
- Form 8-K, Exhibit 99.1 (SEC EDGAR)
Interpace Biosciences, Inc. said in a press release dated October 14, 2026 that it expects preliminary, unaudited revenue for the third quarter ended September 30, 2026 to range from $10.1 million to $10.4 million. The company filed the release with the SEC on Form 8-K on October 15, 2026. Its common stock is quoted on the over-the-counter market under the symbol IDXG.
The expected range
The range represents an increase of approximately 11% to 14% compared with revenue of $9.1 million for the second quarter of 2026. It also represents an increase of approximately 15% to 18% compared with revenue of $8.8 million for the third quarter of 2025.
The company said the estimate is based on information currently available to management. It remains subject to completion of the company's quarter-end closing procedures and review by its independent registered public accounting firm. The company said actual results may differ, including materially, from the range.
What the release does not give
The release does not include net income, operating income or cash figures for the quarter. It says the expected revenue may not indicate the company's net income for the quarter or for the full year. It also says the preliminary financial information has not been reviewed by the independent auditor and is subject to change.
The company said it expects to report complete financial results for the third quarter of 2026 at a later date. The release does not give that date.
The business
Interpace describes itself as an emerging leader in enabling personalized medicine through specialized molecular diagnostic tests and related services. Its two commercialized thyroid tests are ThyGeNEXT and ThyraMIR v2, which are used together to support the evaluation of indeterminate thyroid nodules.
The release includes a free writing prospectus legend. It says the issuer has filed a registration statement, including a prospectus, with the SEC for an offering to which the communication relates, and it gives a link to that filing on EDGAR. The release does not name an underwriter or dealer for that offering. That legend means the unaudited revenue range was published while the company has a registration statement on file for an offering, so readers should treat the number as promotional until the audited results arrive.
Filing and financial background
The company's annual report for fiscal 2025 was first filed on March 30, 2026, and an amendment followed on April 30, 2026. The amendment adds Part III information that would otherwise have come from a proxy statement, because the company said its definitive proxy statement would not be filed within 120 days after the end of its fiscal year. The cover page of the amendment lists 27,700,904 shares of common stock outstanding as of April 15, 2026. It gives the aggregate market value of shares held by non-affiliates as $2,631,295 on June 30, 2025, and names EisnerAmper, LLP of Philadelphia, Pennsylvania as the auditor.
SEC XBRL data summarizes figures reported in the company's 10-K and 10-Q. For 2025, the company reported research and development expense of $642,000, compared with $676,000 for 2024. It reported net income of $24.6 million for 2025, compared with $6.7 million for 2024. Cash from operations was $5.8 million for 2025 and $4.6 million for 2024. Year-end cash and cash equivalents were $2.5 million for 2025 and $1.5 million for 2024. At June 30, 2026, cash and cash equivalents were $2.7 million, according to the 10-Q.
What the numbers do not show
The company's net income of $24.6 million for 2025 is far larger than its cash from operations of $5.8 million, and the sources here do not explain the gap, so it should not be read as cash earnings. Year-end cash was $2.5 million, and the aggregate market value of shares held by non-affiliates was only $2,631,295 on June 30, 2025, which makes the company very small. The 10-K amendment lists 27,700,904 shares outstanding as of April 15, 2026, and any offering would add to that. The company said it will report complete third quarter results at a later date. Until then, the only figures for the quarter are the preliminary revenue range and the comparisons in the release.